Speakers From AbbVie, National Institutes of Health, National Organization for Rare Disorders, NYU Grossman School of Medicine and Verily Share Insights on How Medical Innovation Is Disrupting Policy—and What Needs to Come Next.
A host of breakthrough innovations are reshaping the ways we prevent, diagnose, treat and manage a full range of medical conditions. Advances in the generation and cellular delivery of RNA have enabled the development of mRNA vaccines across a broad array of applications—from COVID to cancer. Although in its infancy, implanted brain-computer interface technology offers new hope to the 5.4 million paralyzed Americans, restoring voluntary motor impulses even to patients suffering from severe paralysis. Cell and gene therapies bring a paradigm shift to people with genetic and degenerative diseases, moving us beyond treating symptoms to repairing the body. Artificial intelligence is increasing the accuracy of diagnosis and treatment, driving improved outcomes, predicting infectious disease spread and showing potential for enhancing drug development. In fact, in headline-making news, Insilico Medicine announced the world’s first phase 1 clinical trial of a drug developed from scratch using AI.
These examples are just the tip of the iceberg. Groundbreaking technologies and treatments are catapulting us into a new age of medicine—and presenting exciting possibilities for patients whose conditions may have seemed hopeless just a few years ago. But can our health care policy landscape shift as quickly as our scientific one? Is our regulatory framework lagging behind the reality of our new medical environment? In a new webinar from Manatt, NYU Law and NYU Wagner, a panel of thought leaders from across the health care ecosystem will examine the promise and challenges of medical innovation—and the impact of scientific disruption on health care policy—from industry, regulatory, physician and patient perspectives. Key topics include:
- A review of current policies and regulations governing medical innovation
- The ways that scientific advances are disrupting health care policy—and the changes needed to keep pace with next-generation treatments and technologies
- A look at the clinical trial process—and practical and ethical issues around access to investigational therapies
- The balance between safety and innovation—and the challenge of expediting approvals while protecting patients
- Next steps forward—and how new policies can help transform the translational science process to bring new treatments and cures to patients faster
P.S. The webinar provides a “first look” at the kind of unique, interdisciplinary perspective that our groundbreaking NYU Law + NYU Wagner Master of Science in Health Law and Strategy program—created in collaboration with Manatt Health—will provide. To learn more, click here.
- Charles Klippel, Faculty Co-Director, Master of Science in Health Law and Strategy, and Professor of Practice, NYU Law
- Amy Abernethy, M.D., Ph.D., President, Clinical Studies Platforms, Verily
- Alison Bateman-House, M.P.H., Ph.D., Assistant Professor, Department of Population Health, NYU Grossman School of Medicine
- Christopher Boone, Ph.D., Vice President, Global Head of HEOR, AbbVie, Inc.and Adjunct Assistant Professor of Health Administration, NYU Wagner
- Joni Rutter, Ph.D., Director, National Center for Advancing Translational Sciences, National Institutes of Health
- Heidi Ross, Vice President, Policy and Regulatory Affairs, National Organization for Rare Disorders (NORD)
- Rachel Sher, Partner, Manatt Health
Date and Time
Wednesday, February 1
If you would like to receive an audio transcript of this webinar due to accessibility issues, please email us at email@example.com.
This program does not constitute legal advice, nor does it establish an attorney-client relationship. Views expressed by presenters are strictly their own and should not be construed to be the views of Manatt or attributed to Manatt.